Home - Translational Lung Cancer Research

New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies

During the last decade we have seen many changes in the field of Lung Pathology, and had to keep with the immense progress: new therapy options for lung cancer patients have changed our practice and required to learn from disciplines such as genetics and immunology. The aim of this series is to discuss new developments or already present techniques and confront pathologists with this news, hopefully convincing them to adjust the daily practice accordingly.

Lung Cancer Multidisciplinary Care

The papers in this series explore important aspects of MDT care including the early introduction of palliative care, the impact on advanced disease, optimal staging in the context of the MDT, gaps in our understanding of how to best implement and test the effects of MDTs, patient outcomes associated with MDT care, lung cancer surgery in the MDT setting and optimized approaches to data systems for the MDT.

Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting

Since its inception 25 years ago, Pulmonary Pathology Society has been continuously committed to support education, research and modern clinical practice in pulmonary pathology. In June 2019, Pulmonary Pathology Society Biennial Meeting took place in Dubrovnik, Croatia. This series covers selected presented topics including the classification of lung adenocarcinomas and neuroendocrine tumors, challenges and barriers in testing for predictive biomarkers for targeted therapies and immunotherapies, and finally advances in the diagnosis and prognostication of pleural mesothelioma.

New Impact Factor for Translational Lung Cancer Research: 5.132

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2019 citation year: 5.132.

AME entered an official partnership with Publons to enhance wide-ranging recognition for reviewers

AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as of April 2020. Around 60 AME journals’ peer review systems are now integrated seamlessly into the Publons platform (https://publons.com/about/home). The partnership was done to recognize our expert peer reviewers spontaneously for their review contribution.

Oligometastatic NSCLC: definition and treatment opportunities (Ongoing)

This focused issue on “Oligometastatic NSCLC: definition and treatment opportunities” is edited by Drs. Maurizio V. Infante and Thierry Berghmans.

Implementation of CT-based screening of lung cancer (Ongoing)

This focused issue on “Implementation of CT-based screening of lung cancer” is edited by Dr. Witold Rzyman.

Implementation of transparent peer review at Translational Lung Cancer Research

With a commitment to openness and accountability, and to increase the level of transparency throughout our peer review process, our editorial office has decided to implement a transparent peer review process as an option for all manuscripts submitted to TLCR from March 18, 2020.

Immunotherapy in other thoracic malignancies and uncommon populations (Ongoing)

This focused issue on “Immunotherapy in other thoracic malignancies and uncommon populations” is edited by Drs. Jordi Remon and Benjamin Besse.

TLCR Annual Report 2019

In the past 2019, Translational Lung Cancer Research made great progress on publication quality and quantity in view of its publication number, pageviews, citations and PubMed retrievals. Furthermore, TLCR has published a series of high-quality focused issues guest-edited by a number of excellent experts who have been actively involved in the forefront of scientific research and clinical practice.

‹ ›

Vol 9, No 5 (October, 2020)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Editorial

Can CT radiomics differentiate benign from malignant N2 adenopathy in non-small cell lung cancer

Robert J. Cerfolio, William H. Moore

PDF Pages: 1710-1711 Full Text COI Form Open Access

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer

Pierpaolo Correale, Rocco Giannicola, Rita Emilena Saladino, Valerio Nardone, Luigi Pirtoli, Pierfrancesco Tassone, Amalia Luce, Salvatore Cappabianca, Marianna Scrima, Pierosandro Tagliaferri, Michele Caraglia

PDF Pages: 1712-1719 Full Text COI Form Open Access

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?

Conor E. Steuer, Suresh S. Ramalingam

PDF Pages: 1720-1723 Full Text COI Form Open Access

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?

Fabrizio Tabbò, Maria Lucia Reale, Silvia Novello

PDF Pages: 1724-1727 Full Text COI Form Open Access

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?

Surein Arulananda, Thomas John

PDF Pages: 1728-1731 Full Text COI Form Open Access

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined

Christos Chouaïd, Nathalie Baize, Isabelle Monnet

PDF Pages: 1732-1735 Full Text COI Form Open Access

Original Article

Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care

Robert D. Schouten, Lucie Egberink, Mirte Muller, Cornedine J. De Gooijer, Erik van Werkhoven, Michel M. van den Heuvel, Paul Baas

PDF Pages: 1736-1748 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer

Hyun Ae Jung, Sook Young Woo, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Jong-Mu Sun

PDF Pages: 1749-1758 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples

Herbert Ho-Fung Loong, Nan Du, Chunyan Cheng, Hanqing Lin, Jian Guo, Gen Lin, Mingjiang Li, Tao Jiang, Zhihua Shi, Yanzhi Cui, Xianfeng Jin, Jicheng Yao, Yutong Xing, Ming Yao, Kai Wang, Tony S. K. Mok, Lunxu Liu

PDF Pages: 1759-1769 Full Text Reporting Checklist COI Form Open Access

The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis

Bin Wu, Shun Lu

PDF Pages: 1770-1784 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Treatments for combined small cell lung cancer patients

Jiaxi He, Songhui Xu, Hui Pan, Shuben Li, Jianxing He

PDF Pages: 1785-1794 Full Text Reporting Checklist Peer Review File COI Form Open Access

Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer

Joanna Kapeleris, Arutha Kulasinghe, Majid Ebrahimi Warkiani, Connor Oleary, Ian Vela, Paul Leo, Peter Sternes, Kenneth O’Byrne, Chamindie Punyadeera

PDF Pages: 1795-1809 Full Text Data Sharing Statement COI Form Open Access

SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer

Ilaria Attili, Laura Bonanno, Niki Karachaliou, Jillian Wilhelmina Paulina Bracht, Jordi Berenguer, Carles Codony-Servat, Jordi Codony-Servat, Erika Aldeguer, Ana Gimenez-Capitan, Alessandro Dal Maso, Matteo Fassan, Imane Chaib, Miguel Angel Molina-Vila, Antonio Passaro, Filippo de Marinis, Giulia Pasello, Valentina Guarneri, Pier Franco Conte, Rafael Rosell

PDF Pages: 1810-1821 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Significant diaphragm elevation suggestive of phrenic nerve injury after thoracoscopic lobectomy for lung cancer: an underestimated problem

Luigi Ventura, Weigang Zhao, Tangbing Chen, Zhexin Wang, Jian Feng, Zhitao Gu, Chunyu Ji, Wentao Fang

PDF Pages: 1822-1830 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Interactions between the enhanced recovery after surgery pathway and risk factors for lung infections after pulmonary malignancy operation

Xianfei Zhang, Runsen Jin, Yuyan Zheng, Dingpei Han, Kai Chen, Jian Li, Hecheng Li

PDF Pages: 1831-1842 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Establishment and validation of a mathematical diagnosis model to distinguish benign pulmonary nodules from early non-small cell lung cancer in Chinese people

Qiang Wei, Weizhen Fang, Xi Chen, Zhongzhen Yuan, Yumei Du, Yanbin Chang, Yonghong Wang, Shulin Chen

PDF Pages: 1843-1852 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study

Chun-Wei Xu, Wen-Xian Wang, Dong Wang, Qi-Ming Wang, Xing-Xiang Pu, You-Cai Zhu, Jian-Hui Huang, Zong-Yang Yu, Zhao-Lei Cui, Xiao-Hui Chen, Jin-Luan Li, Yong Fang, Hong Wang, Wu Zhuang, Shi-Jie Lan, Xin Cai, Yin-Bin Zhang, Wen-Bin Gao, Li-Ping Wang, Ke-Lin She, Chuang-Zhou Rao, Yue-Fen Zhou, Mei-Yu Fang, Li-Yun Miao, Lei Lei, Tang-Feng Lv, Yong Song, on behalf of AME Lung Cancer Collaborative Group

PDF Pages: 1853-1861 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Stereotactic body radiation therapy for empirically treated hypermetabolic lung lesions: a single-institutional experience identifying the Charlson score as a key prognostic factor

Roman O. Kowalchuk, Michael R. Waters, Sujith Baliga, K. Martin Richardson, Kelly M. Spencer, James M. Larner, Charles R. Kersh

PDF Pages: 1862-1872 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer

Gloria Y. F. Ho, Tao Wang, Hoi-Hin Kwok, Rehana Rasul, Rita Peila, Maria Guzman, Mary S. M. Ip, David C. L. Lam

PDF Pages: 1873-1884 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

ACOT11 promotes cell proliferation, migration and invasion in lung adenocarcinoma

Chaoyang Liang, Xiaowei Wang, Zhenrong Zhang, Fei Xiao, Hongxiang Feng, Qianli Ma, Jingjing Huang, Guangliang Qiang, Dingrong Zhong, Deruo Liu

PDF Pages: 1885-1903 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cells

Michelle Simone Clement, Kristine Raaby Gammelgaard, Anders Lade Nielsen, Boe Sandahl Sorensen

PDF Pages: 1904-1914 Full Text Reporting Checklist Peer Review File COI Form Open Access

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study

Shuta Ohara, Kenichi Suda, Kazuko Sakai, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Toshio Fujino, Takamasa Koga, Akira Hamada, Junichi Soh, Kazuto Nishio, Tetsuya Mitsudomi

PDF Pages: 1915-1923 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

How long is cessation of preoperative smoking required to improve postoperative survival of patients with pathological stage I non-small cell lung cancer?

Toshiyuki Shima, Tomonari Kinoshita, Mao Uematsu, Naomichi Sasaki, Yusuke Sugita, Reiko Shimizu, Masahiko Harada, Tsunekazu Hishima, Hirotoshi Horio

PDF Pages: 1924-1939 Full Text Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

SMO mutations confer poor prognosis in malignant pleural mesothelioma

Diego Signorelli, Claudia Proto, Laura Botta, Annalisa Trama, Marcello Tiseo, Giulia Pasello, Giuseppe Lo Russo, Alessandra Fabbri, Martina Imbimbo, Adele Busico, Arsela Prelaj, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Elena Tamborini, Ugo Pastorino, Filippo de Braud, Gemma Gatta, Marina Chiara Garassino, Monica Ganzinelli

PDF Pages: 1940-1951 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib

Ye Wang, Yanqi He, Panwen Tian, Weiya Wang, Ke Wang, Shannon Chuai, Yalun Li, Shuang Zhao, Yu Wang, Weimin Li

PDF Pages: 1952-1962 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

A pilot study of the ultrathin cryoprobe in the diagnosis of peripheral pulmonary ground-glass opacity lesions

Simin Jiang, Xiaojun Liu, Junxiang Chen, Haifeng Ma, Fangfang Xie, Jiayuan Sun

PDF Pages: 1963-1973 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients

Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, Wei Qiao, Suyu Liu, Jianzhong He, Yawei Qiao, Luyang Yao, Steven H. Lin, James M. Reuben

PDF Pages: 1974-1985 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Is clinical target volume necessary?—a failure pattern analysis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy using intensity-modulated radiotherapy technique

Liqing Zou, Li Chu, Fan Xia, Lijun Zhou, Xi Yang, Jianjiao Ni, Junchao Chen, Zhengfei Zhu

PDF Pages: 1986-1995 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy

Wu-Yan Xia, Xue-Ru Zhu, Wen Feng, Jun Liu, Jia-Ming Wang, Chang-Xing Lv, Qin Zhang, Wen Yu, Xu-Wei Cai, Xiao-Long Fu

PDF Pages: 1996-2007 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Study Protocol

GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/ unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy

Qing Zhou, Ming Chen, Gang Wu, Jian-Hua Chang, Ou Jiang, Jiu-Wei Cui, Guang Han, Qin Lin, Jian Fang, Gong-Yan Chen, Yi-Long Wu

PDF Pages: 2008-2015 Full Text Reporting Checklist COI Form Open Access

Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases

Wenhua Liang, Dan Liu, Min Li, Wei Wang, Zheng Qin, Jian Zhang, Yong Zhang, Yang Hu, Hairong Bao, Yi Xiang, Bo Wang, Jing Wu, Jianyu Sun, Chengping Hu, Xianwei Ye, Xiangyan Zhang, Wei Xiao, Chunmei Yun, Dejun Sun, Wei Wang, Ning Chang, Yunhui Zhang, Jianping Zhao, Xin Zhang, Jinfu Xu, Di Wu, Xiaoju Liu, Yubiao Guo, Qichuan Zhang, Wei Zhang, Lan Yang, Zhanqing Li, Xiaoju Zhang, Baohui Han, Zhaohui Tong, Jianxing He, Jieming Qu, Jian-Bing Fan, Nanshan Zhong

PDF Pages: 2016-2026 Full Text Reporting Checklist COI Form Open Access

Technical Note

Dynamic titanium prosthesis based on 3D-printed replica for chest wall resection and reconstruction

Jacopo Vannucci, Elisa Scarnecchia, Rossella Potenza, Silvia Ceccarelli, Donato Monopoli, Francesco Puma

PDF Pages: 2027-2032 Full Text COI Form Open Access

Review Article

Optimizing current standard of care therapy for stage III non-small cell lung cancer

Vivek Verma, Steven H. Lin

PDF Pages: 2033-2039 Full Text Reporting Checklist COI Form Open Access

A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer

Rahul N. Prasad, Terence M. Williams

PDF Pages: 2040-2050 Full Text Reporting Checklist Peer Review File COI Form Open Access

Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer

Eric K. Singhi, Carl M. Gay

PDF Pages: 2051-2058 Full Text Reporting Checklist COI Form Open Access

Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy

Zhang-Ru Yang, Mi-Na Liu, Jia-Hua Yu, Yun-Hai Yang, Tian-Xiang Chen, Yu-Chen Han, Lei Zhu, Ji-Kai Zhao, Xiao-Long Fu, Xu-Wei Cai

PDF Pages: 2059-2073 Full Text COI Form Open Access

A narrative review of lung cancer cytology in the times of coronavirus: what physicians should know

Pasquale Pisapia, Umberto Malapelle, Maria Salatiello, Rafael Rosell, Giancarlo Troncone

PDF Pages: 2074-2081 Full Text Reporting Checklist COI Form Open Access

A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy

Shuyan Li, Xiao Chu, Luxi Ye, Jianjiao Ni, Zhengfei Zhu

PDF Pages: 2082-2096 Full Text Reporting Checklist COI Form Open Access

Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy

Tiantian Guo, Liqing Zou, Jianjiao Ni, Xiao Chu, Zhengfei Zhu

PDF Pages: 2097-2112 Full Text Reporting Checklist COI Form Open Access

A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation

Jorge J. García, Luis E. Raez, Daniel Rosas

PDF Pages: 2113-2119 Full Text Reporting Checklist COI Form Open Access

Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review

Wu-Yan Xia, Wen Feng, Chen-Chen Zhang, Yu-Jia Shen, Qin Zhang, Wen Yu, Xu-Wei Cai, Xiao-Long Fu

PDF Pages: 2120-2136 Full Text Reporting Checklist COI Form Open Access

Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review

Liyang Jiang, Xiangjiao Meng, Xianguang Zhao, Ligang Xing, Jinming Yu

PDF Pages: 2137-2144 Full Text Reporting Checklist COI Form Open Access

Case Report

Novel ALK mutation with durable response to brigatinib—a case report

Hira Latif, Stephen V. Liu

PDF Pages: 2145-2148 Full Text Reporting Checklist COI Form Open Access

Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report

Ana Rita Lopes, Alessandro Russo, Andrew Y. Li, Michael G. McCusker, Jeffrey Myles Kroopnick, Katherine Scilla, Ranee Mehra, Christian Rolfo

PDF Pages: 2149-2156 Full Text Reporting Checklist COI Form Open Access

A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient

Pengqiang Gao, Hao Chen, Taidui Zeng, Weidong Wu, Guobing Xu, Chi Xu, Bin Zheng, Yong Zhu, Wei Zheng, Chun Chen

PDF Pages: 2157-2160 Full Text Reporting Checklist COI Form Open Access

Editorial Commentary

New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study?

Helen Morgan, Emma L. O’Dowd, Arjun Nair, David R. Baldwin

PDF Pages: 2161-2164 Full Text COI Form Open Access

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression

Pamela Abdayem, David Planchard

PDF Pages: 2165-2172 Full Text COI Form Open Access

Finding chinks in the osimertinib resistance armor

Jose Luis Leal, Benjamin Solomon, Thomas John

PDF Pages: 2173-2177 Full Text COI Form Open Access

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer

Toshimitsu Yamaoka, Junji Tsurutani, Hironori Sagara, Tohru Ohmori

PDF Pages: 2178-2183 Full Text COI Form Open Access

The KEYNOTE-189 trial as a new paradigm making cure a reality for metastatic non-squamous non-small cell lung cancer

Yanye Wang, Shikang Zhao, Jun Chen, Song Xu

PDF Pages: 2184-2187 Full Text COI Form Open Access

Letter to the Editor

Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib

Yibin Li, Yantang Lin, Jingxun Wu, Feng Ye

PDF Pages: 2188-2190 Full Text COI Form Open Access

Editorial on New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies¹

New developments in lung cancer diagnosis and pathological patient management strategies

Helmut Popper

PDF Pages: 2191-2193 Full Text COI Form Open Access

Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists

Luka Brcic, Izidor Kern

PDF Pages: 2194-2198 Full Text COI Form Open Access

Review Article on New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies¹

New insights into the interaction of the immune system with non-small cell lung carcinomas

Paul Hofman

PDF Pages: 2199-2213 Full Text COI Form Open Access

Patient-derived cell line, xenograft and organoid models in lung cancer therapy

Ku-Geng Huo, Elisa D’Arcangelo, Ming-Sound Tsao

PDF Pages: 2214-2232 Full Text COI Form Open Access

New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential therapeutic impacts

Sylvie Lantuejoul, Lynnette Fernandez-Cuesta, Francesca Damiola, Nicolas Girard, Anne McLeer

PDF Pages: 2233-2244 Full Text COI Form Open Access

How should molecular findings be integrated in the classification for lung cancer?

Yin P. Hung, Lucian R. Chirieac

PDF Pages: 2245-2254 Full Text COI Form Open Access

A narrative review of digital pathology and artificial intelligence: focusing on lung cancer

Taro Sakamoto, Tomoi Furukawa, Kris Lami, Hoa Hoang Ngoc Pham, Wataru Uegami, Kishio Kuroda, Masataka Kawai, Hidenori Sakanashi, Lee Alex Donald Cooper, Andrey Bychkov, Junya Fukuoka

PDF Pages: 2255-2276 Full Text Reporting Checklist Peer Review File COI Form Open Access

Primary tumor and metastasis—sectioning the different steps of the metastatic cascade

Helmut Popper

PDF Pages: 2277-2300 Full Text COI Form Open Access

Erratum

Erratum to clinical impact of the lung tissue transcriptome in a teenager with multifocal invasive mucinous adenocarcinoma—a case report

Emma Di Carlo, Giuseppe Cipollone, Felice Mucilli, Carlo Sorrentino

PDF Pages: 2301 Full Text Open Access

Disclosure:

1. The series “New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Helmut Popper served as the unpaid Guest Editor for the series.

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Development of a nomogram for predicting the operative mortality of patients who underwent pneumonectomy for lung cancer: a population-based analysis

Xiangyang Yu, Shugeng Gao, Qi Xue, Fengwei Tan, Yushun Gao, Yousheng Mao, Dali Wang, Jun Zhao, Yin Li, Feng Wang, Hong Cheng, Chenguang Zhao, Juwei Mu

cGAS-STING pathway expression as a prognostic tool in NSCLC

Kristine Raaby Gammelgaard, Birgitte Sandfeld-Paulsen, Stine Høvring Godsk, Christina Demuth, Peter Meldgaard, Boe Sandahl Sorensen, Martin Roelsgaard Jakobsen

MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer

Shijun Zhao, Donghui Hou, Xiaomin Zheng, Wei Song, Xiaoqing Liu, Sicong Wang, Lina Zhou, Xiuli Tao, Lv Lv, Qi Sun, Yujing Jin, Lieming Ding, Li Mao, Ning Wu

Association between aspirin use and lung cancer incidence depends on high-frequency use, bodyweight, and age in U.S. adults

Xuesi Dong, Jieyu He, Lijuan Lin, Ying Zhu, Chao Chen, Li Su, Yang Zhao, Ruyang Zhang, Yongyue Wei, Feng Chen, David C. Christiani

High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)

Florian Kocher, Arno Amann, Kai Zimmer, Simon Geisler, Dietmar Fuchs, Renate Pichler, Dominik Wolf, Katharina Kurz, Andreas Seeber, Andreas Pircher

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)

Shinji Takeuchi, Noriko Yanagitani, Takashi Seto, Yoshihiro Hattori, Kadoaki Ohashi, Masahiro Morise, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto, Makoto Nishio, Shizuko Takahara, Takahiro Kawakami, Yasuhito Imai, Kenichi Yoshimura, Azusa Tanimoto, Akihiro Nishiyama, Toshinori Murayama, Seiji Yano

Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab

Doran Ksienski, Elaine S. Wai, Deepu Alex, Nicole S. Croteau, Ashley T. Freeman, Angela Chan, Tiffany Patterson, Melissa Clarkson, Leathia Fiorino, Zia Poonja, David Fenton, Sarah Irons, Mary Lesperance

The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment

Shenglin Ma, Meiqi Shi, Xueqin Chen, Yong Wang, Zhenhua Yang, Analyn Lizaso, Min Li, Haiyan Li, Lu Zhang, Xinru Mao, Xingxiang Xu, Yong Song

Performance of various risk prediction models in a large lung cancer screening cohort in Gdańsk, Poland—a comparative study

Marcin Ostrowski, Franciszek Bińczyk, Tomasz Marjański, Robert Dziedzic, Sylwia Pisiak, Sylwia Małgorzewicz, Mariusz Adamek, Joanna Polańska, Witold Rzyman

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation

Yishan Yu, Linlin Wang, Shufen Cao, Siming Gao, Weili Wang, Lianne Mulvihill, Mitchell Machtay, Pingfu Fu, Jinming Yu, Feng-Ming (Spring) Kong

Review Article

Lung cancer screening: targeting the hard to reach—a review

Guido Van Hal, Paloma Diab Garcia

Challenges in the target volume definition of lung cancer radiotherapy

Susan Mercieca, José S. A. Belderbos, Marcel van Herk

Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer

Steven Bozinovski, Amanda Vannitamby, Kanishka Rangamuwa, Savreet Aujla, Hao Wang, Christian Aloe, Louis Irving, Tracy T. Leong, Daniel P. Steinfort

The radiologist’s role in lung cancer screening

Annemiek Snoeckx, Caro Franck, Mario Silva, Mathias Prokop, Cornelia Schaefer-Prokop, Marie-Pierre Revel

Immunotherapy in small cell lung cancer: one step at a time: a narrative review

Daphne W. Dumoulin, Anne-Marie C. Dingemans, Joachim G. J. V. Aerts, Jordi Remon, Dirk K. M. De Ruysscher, Lizza E. L. Hendriks

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy

Ben G. L. Vanneste, Evert J. Van Limbergen, Kobe Reynders, Dirk De Ruysscher

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won

Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V. Scagliotti

Immunotherapy in oncogene addicted non-small cell lung cancer

Luke McLean, Jose Luis Leal, Benjamin J. Solomon, Thomas John

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer

Ibiayi Dagogo-Jack, Lauren L. Ritterhouse

Lung cancer screening and smoking cessation efforts

Dana Moldovanu, Harry J. de Koning, Carlijn M. van der Aalst

Mediastinal staging for non-small-cell lung cancer

Virginia Leiro-Fernández, Alberto Fernández-Villar

Lung cancer screening: who pays? who receives?—the Chinese perspective

Yang Zhang, Haiquan Chen

Minimal invasive surgery in locally advanced N2 non-small cell lung cancer

Ana Karina Patané

Should sublobar resection be offered for screening-detected lung nodules?

Alan D. L. Sihoe

Managing of screening-detected sub-solid nodules—a European perspective

Sara Ricciardi, Richard Booton, Renè Horsleben Petersen, Maurizio Infante, Marco Scarci, Giulia Veronesi, Giuseppe Cardillo

Dose and fractionation schedules in radiotherapy for non-small cell lung cancer

Lucyna Kepka, Joanna Socha

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy

Kenichi Suda, Tetsuya Mitsudomi

Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?

Anton Schreuder, Ernst T. Scholten, Bram van Ginneken, Colin Jacobs

Evolving target volume concepts in locally advanced non-small cell lung cancer

Ursula Nestle, Cecile Le Pechoux, Dirk De Ruysscher

Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival

Ana Casal-Mouriño, Alberto Ruano-Ravina, María Lorenzo-González, Ángeles Rodríguez-Martínez, Alexandra Giraldo-Osorio, Leonor Varela-Lema, Tara Pereiro-Brea, Juan Miguel Barros-Dios, Luis Valdés-Cuadrado, Mónica Pérez-Ríos

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello

Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer

Caroline Huynh, Logan A. Walsh, Jonathan D. Spicer

How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?

Simon Ekman

Implementation of lung cancer screening: what are the main issues?

Carlijn M. van der Aalst, Kevin ten Haaf, Harry J. de Koning, for the 4-IN-THE-LUNG-RUN Consortium

Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer

Akira Hamada, Junichi Soh, Tetsuya Mitsudomi

Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas

Matthias S. Matter, Obinna Chijioke, Spasenija Savic, Lukas Bubendorf

Latest CT technologies in lung cancer screening: protocols and radiation dose reduction

Marleen Vonder, Monique D. Dorrius, Rozemarijn Vliegenthart

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations

Roberto Ferrara, Diego Signorelli, Claudia Proto, Arsela Prelaj, Marina Chiara Garassino, Giuseppe Lo Russo

Managing screening-detected subsolid nodules—the Asian perspective

Masaaki Sato, Shun-Mao Yang, Dong Tian, Nakajima Jun, Jang-Ming Lee

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

Lizza E. L. Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans, Lizza Elisabeth Lucia Hendriks

Controversies in the role of radiotherapy in pleural mesothelioma

Gerard G. Hanna, Thomas John, David L. Ball

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer

Boris Duchemann, Jordi Remon, Marie Naigeon, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Edouard Auclin, Aude Desnoyer, Benjamin Besse, Nathalie Chaput

Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease

Francesco Passiglia, Valeria Cetoretta, Marco De Filippis, Valerio Napoli, Silvia Novello

Exploring natural killer cell immunology as a therapeutic strategy in lung cancer

Jonas B. Hess, Kate D. Sutherland, Sarah A. Best

Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer

Olwen Leaman Alcibar, Ernest Nadal, Inmaculada Romero Palomar, Arturo Navarro-Martin

Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Francesca Bersani, Deborah Morena, Francesca Picca, Alessandro Morotti, Fabrizio Tabbò, Paolo Bironzo, Luisella Righi, Riccardo Taulli

Overcoming TKI resistance in fusion-driven NSCLC: New generation inhibitors and rationale for combination strategies

Alessandro Russo, Andrés F. Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo

Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer

Monika Pradhan, Mathieu Chocry, Don L. Gibbons, Boris Sepesi, Tina Cascone

Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issues

Francesca Casaluce, Cesare Gridelli

Lung cancer screening strategy for non-high-risk individuals: a narrative review

Fangqiu Fu, Yaodong Zhou, Yang Zhang, Haiquan Chen

Preoperative and postoperative radiotherapy (RT) for non-small cell lung cancer: still an open question

Paul Van Houtte, Luigi Moretti, Florian Charlier, Martine Roelandts, Dirk Van Gestel

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review

Ana Ortega-Franco, Virginia Calvo, Fabio Franco, Mariano Provencio, Raffaele Califano

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)

Bing Xia, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou, Ross A. Soo

Induction treatment in patients with stage III non-small cell lung cancer

Ramón Palmero, Noelia Vilariño, Arturo Navarro-Martín, Ernest Nadal

Screen-detected solid nodules: from detection of nodule to structured reporting

Mario Silva, Gianluca Milanese, Roberta E. Ledda, Ugo Pastorino, Nicola Sverzellati

Decade in review: a new era for RET-rearranged lung cancers

Noura J. Choudhury, Alexander Drilon

Holding our breath: the promise of tissue-resident memory T cells in lung cancer

Claire Marceaux, Clare E. Weeden, Claire L. Gordon, Marie-Liesse Asselin-Labat

Prophylactic cranial irradiation in SCLC

Rafal Suwinski

Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target

Danish Safi, Taher Abu Hejleh, Muhammad Furqan

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer

Roxana Reyes, Noemi Reguart

Radiotherapy for thymic epithelial tumours: a review

Krisztian Süveg, Paul Martin Putora, Markus Joerger, Thomas Iseli, Galina Farina Fischer, Karlheinz Ammann, Markus Glatzer

Editorial

Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?

Ramon Andrade De Mello, Jin-Hui Zhu, Jairo Iavelberg, Artur Henrique Potim, Débora Simonetti, José Antônio Silva Júnior, Pedro Castelo-Branco, Daniel Humberto Pozza, Carla Chizuru Tajima, Maria Tolia, Georgio Antoniou

Prognostic models for immunotherapy: emerging factors for an evolving treatment landscape

Howard West

Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?

Walter Weder, Katarzyna Furrer, Isabelle Opitz

The Gut Microbiome and its interaction with health, disease, treatment response and toxicity in patients advanced cancer: focus on lung cancer and immunotherapy

Nadina Tinsley, Natalie Cook

Endocrine immune-related adverse events: a double-edged sword?

Michelle Rengarajan, Justin F. Gainor

Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins

Kah Yee Goh, Wan-Teck Lim

Radiomics signature for prediction of N2 disease: fascinating but still a long way to go for clinical application

Kwon Joong Na, Hongyoon Choi, Young Tae Kim

Case Report

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report

Xuan Wu, Hanqiong Zhou, Zhen He, Zhe Zhang, Wen Feng, Jiuzhou Zhao, Haiyang Chen, Shuai Wang, Wei Wang, Qiming Wang

Editorial Commentary

Perspective of gene therapy with replication competent viruses

Makoto Maemondo

Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”

Wickii T. Vigneswaran, Muaiad Kittaneh

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.